Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fresh Tracks Therapeutics Inc FRTX

Healthcare Biotechnology
Fresh Tracks Therapeutics, Inc. is not engaged in any business activities. The Company is in the process of dissolution.

Recent & Breaking News (OTCPK:FRTX)

Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire August 11, 2022

Brickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022

GlobeNewswire August 2, 2022

Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire July 20, 2022

Brickell Biotech to Participate at William Blair Biotech Focus Conference 2022

GlobeNewswire July 6, 2022

Brickell Biotech Announces 1-For-45 Reverse Stock Split

GlobeNewswire July 1, 2022

Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02

GlobeNewswire May 19, 2022

Brickell Biotech Reports First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 12, 2022

Brickell Biotech to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12, 2022

GlobeNewswire May 5, 2022

Brickell Biotech Announces Adjournment of Annual Meeting of Stockholders

GlobeNewswire May 3, 2022

Brickell Biotech Announces Sale of Sofpironium Bromide to Botanix Pharmaceuticals

GlobeNewswire May 3, 2022

Brickell Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

GlobeNewswire March 15, 2022

Brickell Biotech Selected for a Late-Breaking Oral Presentation of US Phase 3 Pivotal Cardigan I and Cardigan II Study Results for Sofpironium Bromide Gel, 15% at the 2022 AAD Annual Meeting

GlobeNewswire March 10, 2022

Brickell Biotech to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 15, 2022

GlobeNewswire March 8, 2022

Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune and Inflammatory Diseases from Carna Biosciences

GlobeNewswire February 2, 2022

Brickell Biotech Reports Third Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire November 9, 2021

Brickell Biotech to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9, 2021

GlobeNewswire November 1, 2021

Brickell Biotech Prices Public Offering of Common Stock

GlobeNewswire October 28, 2021

Brickell Biotech Announces Proposed Underwritten Public Offering of Common Stock

GlobeNewswire October 27, 2021

Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance on all Primary and Secondary Endpoints, from Both U.S. Phase 3 Pivotal Clinical Studies of Sofpironium Bromide Gel, 15% in Primary Axillary Hyperhidrosis Patients

GlobeNewswire October 7, 2021

Brickell Biotech to Host Key Opinion Leader Webinar on DYRK1A and its Role in Autoimmunity

GlobeNewswire September 17, 2021